This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Dec;17(12):1239-1240.

doi: 10.1016/S1473-3099(17)30643-6.

Proton-pump inhibitors and glecaprevir plus pibrentasvir in HCV infection

Guo Yu¹, Guo-Fu Li², Hong-Hao Zhou³

Affiliations

Affiliations

¹ Drug Clinical Trial Institution, Subei People's Hospital, Yangzhou, 225001, China; Department of Gastrointestinal Surgery, Subei People's Hospital, Yangzhou, China; Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
² Drug Clinical Trial Institution, Subei People's Hospital, Yangzhou, 225001, China; Department of Pharmaceutics, University of Florida, Gainesville, FL, 32610, USA. Electronic address: guofu.g.li@gmail.com.
³ Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.

PMID: 29173883
DOI: 10.1016/S1473-3099(17)30643-6

Comment

Proton-pump inhibitors and glecaprevir plus pibrentasvir in HCV infection

Guo Yu et al. Lancet Infect Dis. 2017 Dec.

. 2017 Dec;17(12):1239-1240.

doi: 10.1016/S1473-3099(17)30643-6.

Authors

Guo Yu¹, Guo-Fu Li², Hong-Hao Zhou³

Affiliations

¹ Drug Clinical Trial Institution, Subei People's Hospital, Yangzhou, 225001, China; Department of Gastrointestinal Surgery, Subei People's Hospital, Yangzhou, China; Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
² Drug Clinical Trial Institution, Subei People's Hospital, Yangzhou, 225001, China; Department of Pharmaceutics, University of Florida, Gainesville, FL, 32610, USA. Electronic address: guofu.g.li@gmail.com.
³ Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.

PMID: 29173883
DOI: 10.1016/S1473-3099(17)30643-6

No abstract available

PubMed Disclaimer

Comment in

Proton-pump inhibitors and glecaprevir plus pibrentasvir in HCV infection - Authors' reply.
Forns X, Mensa FJ. Forns X, et al. Lancet Infect Dis. 2017 Dec;17(12):1240. doi: 10.1016/S1473-3099(17)30644-8. Lancet Infect Dis. 2017. PMID: 29173884 No abstract available.

Comment on

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Forns X, et al. Lancet Infect Dis. 2017 Oct;17(10):1062-1068. doi: 10.1016/S1473-3099(17)30496-6. Epub 2017 Aug 14. Lancet Infect Dis. 2017. PMID: 28818546 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations